Table 2.
Results of log-rank tests
| Factor | 4-year bRFS (%) (95% CI) | p value |
|---|---|---|
| Pathologic tumor stage | < 0.001 | |
| T1-2 | 79.2 (66.0-92.3) | |
| T3-4 | 31.7 (17.0-46.4) | |
| Surgical margin | 0.652 | |
| Positive | 48.6 (32.0-65.1) | |
| Negative | 57.1 (42.7-71.4) | |
| Gleason score | 0.189 | |
| ≤ 7 | 58.9 (44.5-73.3) | |
| ≥ 8 | 35.2 (14.7-51.5) | |
| Preoperative PSA (ng/ml) | 0.037 | |
| < 10 | 62.0 (47.7-76.3) | |
| ≥ 10 | 39.3 (22.5-56.0) | |
| Pre-RT PSA (ng/ml) | 0.620 | |
| < 0.25 | 54.5 (37.5-71.6) | |
| ≥ 0.25 | 45.9 (30.2-64.9) | |
| PSA doubling time (months) | 0.059 | |
| < 7 | 34.6 (17.5-51.8) | |
| ≥ 7 | 62.2 (46.7-77.7) | |
| RT dose (Gy) | 0.068 | |
| < 64 | 36.8 (15.2-58.5) | |
| ≥ 64 | 51.7 (37.6-65.9) | |
| BED (Gy) (α/β = 1.5) | 0.213 | |
| < 145 | 41.4 (23.5-59.3) | |
| ≥ 145 | 54.3 (39.5-69.1) | |
| Time from RP to RT (months) | 0.310 | |
| < 24 | 45.2 (29.1-61.4) | |
| ≥ 24 | 57.4 (40.9-73.9) | |
| Hormone therapy | 0.627 | |
| Done | 50.5 (20.2-72.9) | |
| Not done | 50.7 (37.6-63.7) |
Abbreviations: bRFS = biochemical relapse-free survival, RT = radiotherapy, PSA = prostate-specific antigen, BED = biological effective dose, RP = radical prostatectomy, CI = confidence interval